Bryan D Kraft1, Kamran Mahmood2, Nicole P Harlan3, Matthew G Hartwig4, Laurie D Snyder2, Hagir B Suliman5, Scott L Shofer2. 1. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine; Center for Hyperbaric Medicine and Environmental Physiology, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina. Electronic address: bryan.kraft@duke.edu. 2. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine. 3. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine; Center for Hyperbaric Medicine and Environmental Physiology, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Dartmouth-Hitchcock, Lebanon, New Hampshire. 4. Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University School of Medicine, Durham, North Carolina. 5. Center for Hyperbaric Medicine and Environmental Physiology, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina.
Abstract
BACKGROUND: Central airway stenosis (CAS) is a severe airway complication after lung transplantation associated with bronchial ischemia and necrosis. We sought to determine whether hyperbaric oxygen therapy (HBOT), an established treatment for tissue ischemia, attenuates post-transplant bronchial injury. METHODS: We performed a randomized, controlled trial comparing usual care with HBOT (2 atm absolute for 2 hours × 20 sessions) in subjects with extensive airway necrosis 4 weeks after transplantation. Endobronchial biopsies were collected at 4, 7, and 10 weeks after transplantation for a quantitative polymerase chain reaction. Coprimary outcomes were incidence of airway stenting and acute cellular rejection (ACR) at 1 year. RESULTS: The trial was stopped after enrolling 20 subjects (n = 10 per group) after a pre-planned interim analysis showed no difference between usual care and HBOT groups in stenting (both 40%), ACR (70% and 40%, respectively), or CAS (40% and 60%, respectively). Time to first stent placement (median [interquartile range]) was significantly shorter in the HBOT group (150 [73-150] vs 186 [167-206] days, p < 0.05). HIF gene expression was significantly increased in donor tissues at 4, 7, and 10 weeks after transplantation but was not altered by HBOT. Subjects who developed CAS or required stenting had significantly higher HMOX1 and VEGFA expression at 4 weeks (both p < 0.05). Subjects who developed ACR had significant FLT1, TIE2, and KDR expression at 4 weeks (all p < 0.05). CONCLUSIONS: Incidence of CAS is high after severe, established airway necrosis after transplantation. HBOT does not reduce CAS severity or stenting. Elevated HMOX1 and VEGFA expressions appear to associate with airway complications. Published by Elsevier Inc.
BACKGROUND: Central airway stenosis (CAS) is a severe airway complication after lung transplantation associated with bronchial ischemia and necrosis. We sought to determine whether hyperbaric oxygen therapy (HBOT), an established treatment for tissue ischemia, attenuates post-transplant bronchial injury. METHODS: We performed a randomized, controlled trial comparing usual care with HBOT (2 atm absolute for 2 hours × 20 sessions) in subjects with extensive airway necrosis 4 weeks after transplantation. Endobronchial biopsies were collected at 4, 7, and 10 weeks after transplantation for a quantitative polymerase chain reaction. Coprimary outcomes were incidence of airway stenting and acute cellular rejection (ACR) at 1 year. RESULTS: The trial was stopped after enrolling 20 subjects (n = 10 per group) after a pre-planned interim analysis showed no difference between usual care and HBOT groups in stenting (both 40%), ACR (70% and 40%, respectively), or CAS (40% and 60%, respectively). Time to first stent placement (median [interquartile range]) was significantly shorter in the HBOT group (150 [73-150] vs 186 [167-206] days, p < 0.05). HIF gene expression was significantly increased in donor tissues at 4, 7, and 10 weeks after transplantation but was not altered by HBOT. Subjects who developed CAS or required stenting had significantly higher HMOX1 and VEGFA expression at 4 weeks (both p < 0.05). Subjects who developed ACR had significant FLT1, TIE2, and KDR expression at 4 weeks (all p < 0.05). CONCLUSIONS: Incidence of CAS is high after severe, established airway necrosis after transplantation. HBOT does not reduce CAS severity or stenting. Elevated HMOX1 and VEGFA expressions appear to associate with airway complications. Published by Elsevier Inc.
Authors: Danny Jonigk; Nicole Izykowski; Johanna Rische; Peter Braubach; Mark Kühnel; Gregor Warnecke; Torsten Lippmann; Hans Kreipe; Axel Haverich; Tobias Welte; Jens Gottlieb; Florian Laenger Journal: Am J Pathol Date: 2015-10-23 Impact factor: 4.307
Authors: Heyman Luckraz; Martin Goddard; Keith McNeil; Carl Atkinson; Linda D Sharples; John Wallwork Journal: Ann Thorac Surg Date: 2006-10 Impact factor: 4.330
Authors: Xinguo Jiang; Joe L Hsu; Wen Tian; Ke Yuan; Mark Olcholski; Vinicio de Jesus Perez; Gregg L Semenza; Mark R Nicolls Journal: J Mol Med (Berl) Date: 2013-09 Impact factor: 4.599
Authors: Andrea Mazzetta; Michele Porzio; Marianne Riou; Benjamin Coiffard; Anne Olland; Tristan Dégot; Joseph Seitlinger; Gilbert Massard; Benjamin Renaud-Picard; Romain Kessler Journal: Ann Transplant Date: 2019-02-14 Impact factor: 1.530
Authors: Philip A Kramer; Saranya Ravi; Balu Chacko; Michelle S Johnson; Victor M Darley-Usmar Journal: Redox Biol Date: 2014-01-10 Impact factor: 11.799
Authors: Annelore Sacreas; Joshua Y C Yang; Bart M Vanaudenaerde; Tara K Sigdel; Juliane M Liberto; Izabella Damm; Geert M Verleden; Robin Vos; Stijn E Verleden; Minnie M Sarwal Journal: PLoS One Date: 2018-10-05 Impact factor: 3.240